Processes and intermediates for preparing fused heterocyclic kinase inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9018378
APP PUB NO 20130310564A1
SERIAL NO

13946189

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This invention relates to intermediates for manufacturing fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, particularly at an industrial level.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MIRATI THERAPEUTICS INC9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Claridge, Stephen William Montreal, CA 22 275
Granger, Marie-Claude LaPrairie, CA 7 74
Isakovic, Ljubomir Beaconsfield, CA 18 357
Mannion, Michael Montreal, CA 24 362
Raeppel, Franck Montreal, CA 22 124
Vaisburg, Arkadii Kirkland, CA 56 936
Zhan, Lijie Montreal, CA 21 255

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 28, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00